S-1: General form for registration of securities under the Securities Act of 1933
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Director GILL SIMBA
3: Initial statement of beneficial ownership of securities-Director GILL SIMBA
8-K: Current report
AgeX Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bailey Gregory
AgeX Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director MINTZ STEVEN
AgeX Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Marshall Richard Peter
AgeX Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HARRIS J MILTON
AgeX Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Gross Remy
AgeX Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Randall Moreadith(6.8%)
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Viegas Tacey
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Moreadith Randall
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Marshall Richard Peter
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer LEDGER STEVEN A
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Director HARRIS J MILTON
AgeX Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Gross Remy
AgeX Therapeutics | 8-K: Current report
AgeX Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Juvenescence Limited(81.4%),JuvVentures (UK) Limited(75.6%)
AgeX Therapeutics | 8-K: AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
No Data